MNRP1685A + bevacizumab + paclitaxel

This is a **combination therapy** comprising three agents: - **MNRP1685A (vesencumab)**: a fully human IgG1 monoclonal antibody targeting **neuropilin-1 (NRP1)**, blocking the VEGF binding domain of NRP1. NRP1 is involved in neural development and blood vessel maturation; MNRP1685A inhibits binding of VEGF, VEGF-B, and placental growth factor 2, leading to vessel immaturity and increased dependency on VEGF for angiogenesis. - **Bevacizumab**: a recombinant monoclonal antibody targeting **vascular endothelial growth factor A (VEGF-A)**, inhibiting angiogenesis. - **Paclitaxel**: a microtubule-stabilizing **chemotherapeutic agent**, promoting apoptosis by interfering with cell division. This triple combination is studied primarily in **patients with advanced solid tumors**, aiming to enhance antiangiogenic and antineoplastic effects through targeting both blood vessel formation (angiogenesis inhibition) and direct tumor cell cytotoxicity[2][6].

Brand names

vesencumab

Other names

anti-neuropilin-1 monoclonal antibody MNRP1685Aanti-neuropilin1 monoclonal antibody MNRP1685Aanti-neuropilin 1 monoclonal antibody MNRP1685A